TickerFacts.

Monte Rosa Therapeutics, Inc. (GLUE): Revenue

Annual figures by period end, from SEC filings.

$123.67M
Year ended 2025-12-31
$28.73M
Trailing 12 months to 2026-06-30
2023-12-31: $02024-12-31: $75.62M2025-12-31: $123.67M$123.67M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$123.67M+63.5%2026-03-17, From 2025-01-01
2024-12-31$75.62Mn/a2026-03-17, From 2024-01-01
2023-12-31$0n/a2025-03-20, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$123.67M+63.5%
Atara Biotherapeutics, Inc. (ATRA)2025-12-31$120.77M-6.3%
Agenus Inc (AGEN)2025-12-31$114.20M+10.4%
ImmunityBio, Inc. (IBRX)2025-12-31$113.29M+668.3%
Beam Therapeutics Inc. (BEAM)2025-12-31$139.74M+120.0%
Century Therapeutics, Inc. (IPSC)2025-12-31$109.16Mn/m
Sutro Biopharma, Inc. (STRO)2025-12-31$102.48M+65.2%
Ginkgo Bioworks Holdings, Inc. (DNA)2025-12-31$170.16M-25.1%
REGENXBIO Inc. (RGNX)2025-12-31$170.44M+104.5%

Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗